jump to navigation
jump to content
Search in Articles and Documents
generate
PDF
-Version of this page
1:
H
ome
(ALT-H)
2:
H
M
A Joint
(ALT-M)
3:
H
u
man Medicines
(ALT-U)
3.1:
H
e
ads of Agencies
(ALT-E)
3.2:
C
MDh
(ALT-C)
3.3:
M
R
I Product Index
(ALT-R)
3.4:
D
i
rectory
(ALT-I)
4:
V
eterinary Medicines
(ALT-V)
You are here:
Human Medicines
>
CMDh
>
About CMDh
> CMDh Activities
3.2.1:
Ab
o
ut CMDh
(ALT-O)
3.2.1.1:
CMDh Com
p
osition
(ALT-P)
3.2.1.2:
CMDh Ac
t
ivities
(ALT-T)
3.2.1.3:
CMDh
W
orkplan
(ALT-W)
3.2.1.4:
CMDh Report
s
(ALT-S)
3.2.1.5:
Co
n
tacts with Representative Organisations
(ALT-N)
3.2.1.6:
Transparenc
y
Measures
(ALT-Y)
3.2.1.7:
Ca
l
endar for CMDh meetings
(ALT-L)
3.2.1.8:
MRF
G
(1995-2005)
(ALT-G)
3.2.2:
Statistics
3.2.3:
Press Releases
3.2.4:
Procedural Guidance
3.2.5:
CMDh-Referrals
3.2.6:
Product Information
3.2.7:
Advice from CMDh
3.2.8:
Templates
3.2.9:
CMD Wor
k
ing Parties / Working Groups
(ALT-K)
3.2.10:
Paediatric Regulation
3.2.11:
Pharmacovigilance Legislation
3.2.12:
Q
uestions & Answers
(ALT-Q)
3.2.13:
Contact Form
3.2.14:
Contact Points
3.2.15:
What's new history
CMDh Activities
CMDh Rules of Procedure
(November 2012)
Functions and tasks for CMDh
Role of the Vice - Chairpersons of the CMDh
(April 2013)
Questions and Answers
Q & A on Requests for Advice from CMDh
Evaluation of the functioning of the CMDh
Further to the questionnaires to CMDh Members and Interested Parties which purpose was to evaluate the functioning of the CMDh and consider how further improvements in the operation of the Group can be achived, the CMDh has published a report with a summary of the responses to the various sections of the questionnaires, and the main actions proposed to address the issues raised.
